Pharma Despite lacking a national champion to bolster its innovative eco-system since the 2007 acquisition of Organon by Schering Plough, the Netherlands nevertheless still sits in fourth position on the 2015 Global Innovation Index. For the healthcare sector, the country’s innovation is notably propelled by a myriad of local success-stories, and…

Pharma The Netherlands is clearly a fertile environment for its 2,200 life science and medtech companies. However, the Dutch ambition to be a frontrunner in new healthcare challenges also comprises an overall approach to treating patients. Aging population, chronic disease, and innovative pharmaceutical treatments’ role in extending patients’ life expectancies have…

Pharma The pharmaceutical industry needs to work harder to demonstrate the value that it delivers to society and to the greater economy by advancing public health outcomes, delegates at the 14th annual eyeforpharma conference in Barcelona have been told. Addressing over a thousand industry stakeholders at Barcelona’s Centre Convencions Internacional, senior…

Paris, November 20th, 2015 Synerlab pursues its consolidation strategy in Europe Synerlab, a leading pharmaceutical manufacturer, announces today the acquisition of Alcala Farma, a prominent Spanish contract development and manufacturing organization (CDMO). Alcala Farma specializes in the development of proprietary formulation, which represents nearly 40% of its total €M 25…

Pharma Multinationals have struggled to adapt their Romanian strategies, but the local production sector appears to be flourishing. Much of this impetus relates directly to EU accession and the harmonization of manufacturing standards. “Initially, it was difficult to enact the transition, because the authorities handed us strict deadlines to make ourselves…

Romania No one can accuse the Romanian government of being lethargic when it comes to healthcare reform. After an unprecedented seven years of zero new molecules being admitted to the state reimbursement list, the pharma industry has suddenly been subjected to a whirlwind of radical refashioning and legislatory upheaval. “The industry…

Romania Once touted by the IMS as one of the “fast followers” among the world’s “pharmerging” nations and feted by the international investor community in the wake of EU accession, Romania’s pharmaceutical industry appears resurgent once more after a number of years on the back burner. In 2014, Romania’s market size…

CPhI Worldwide 2014, held this year in Paris, was the largest ever event held by the organizers, with more than 36,000 attendees and 2,500 exhibitors. PharmaBoardroom was a media partner of this year’s event, and Frederic Boucheseiche, the founding partner and COO of Focus Reports and PharmaBoardroom, was invited to…

R&D As a result of contractions in the domestic market following the European financial crisis, pharma companies based in Spain have been forced to look elsewhere for business, beyond the borders of Spain and Europe to more far-reaching areas of the globe. Thankfully, the authorities helped out to make this process…

cost containment “Cost containment measures are not just a Polish story, but a European reality,” says Marcin Hanczaruk, general manager at Amgen. “The Reimbursement Act is a real revolution, but it has brought both benefits and shortcomings. One consequence is that Poland has the lowest average price of medicine in the European…

Spain’s pharmaceutical industry has been under a lot of pressure in the past few years: public expenditure on pharmaceuticals contracted nearly 29 percent between May 2010 and December 2013. Numerous cost-containment measures, such as increases in co-payments, de-listing hundreds of minor medications and price cuts have all contributed to the…

In PharmaBoardroom’s first coverage of Portugal in 2007, generics represented 16 percent of the country’s pharmaceutical market, a tremendous feat considering laws for generics had only been implemented a few years before. Today, generics represent nearly 40 percent of the market in units, with the aim is to increase this…